Acute Porphyria Drug Database

L01FE01 - Cetuximab
Not porphyrinogenic
NP

Rationale
No CYP-affinity. No conceivable effects on PXR activation. However, side effects such as nausea and vomiting may be potentially porphyrinogenic through reduction in caloric intake.
Chemical description
Cetuximab is a recombinant chimeric (human-murine) monoclonal antibody.
Therapeutic characteristics
Cetuximab is an antineoplastic agent used to treat colorectal cancer with metastases and cancers in the head and neck. It is administered as an intravenous infusion. Common adverse reactions of cetuximab that can be confused with an acute porphyric attack are nausea, vomiting, abdominal pain, diarrhea and dyspnoea. Side effects such as nausea and vomiting may be potentially porphyrinogenic through reduction in caloric intake.
Metabolism and pharmacokinetics
Cetuximab is metabolized in the same way as as endogenous IgG. Non-CYP metabolism.

References

  1. Drug reference publications
  2. McEvoy GK, editor. Cetuximab. The AHFS Drug Information 2008. Bethesda, MD: American Society of Health-System Pharmacists; 2009. Electronic version (25.05.10). #2044
  3. Sweetman SC, editor. Martindale: The complete drug reference. Cetuximab. Pharmaceutical Press 2009. #2046
  4. Summary of Product Characteristics
  5. Norwegian medicines agency. Summary of Product Characteristics (SPC). Erbitux. #2045

Similar drugs
Explore alternative drugs in similar therapeutic classes L01F / L01FE or go back.

 
© NAPOS 2024
An unhandled error has occurred. Reload 🗙